Krisztina M Papp-Wallace

List of Publications by Year
in descending order

83	4,823	87888 38	98798 67
papers	citations	h-index	g-index

85	85	85	4920
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Editorial: Structural and Biochemical Aspects of the Interaction of Î²-Lactamases With State-of-the-Art Inhibitors. Frontiers in Microbiology, 2022, 13, 849324.	3.5	1
2	Structural Characterization of the D179N and D179Y Variants of KPC-2 Î²-Lactamase: Î©-Loop Destabilization as a Mechanism of Resistance to Ceftazidime-Avibactam. Antimicrobial Agents and Chemotherapy, 2022, 66, e0241421.	3.2	22
3	Different Conformations Revealed by NMR Underlie Resistance to Ceftazidime/Avibactam and Susceptibility to Meropenem and Imipenem among D179Y Variants of KPC Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2022, 66, e0212421.	3.2	11
4	The Class A Î²-Lactamase Produced by Burkholderia Species Compromises the Potency of Tebipenem against a Panel of Isolates from the United States. Antibiotics, 2022, 11, 674.	3.7	1
5	In Vitro Antibacterial Activity and In Vivo Efficacy of Sulbactam-Durlobactam against Pathogenic Burkholderia Species. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
6	Cerebrospinal fluid (CSF) augments metabolism and virulence expression factors in Acinetobacter baumannii. Scientific Reports, 2021, 11, 4737.	3.3	16
7	Structural Characterization of Diazabicyclooctane Î²-Lactam â€œEnhancersâ€•in Complex with Penicillin-Binding Proteins PBP2 and PBP3 of Pseudomonas aeruginosa. MBio, 2021, 12, .	4.1	19
8	Staphylococcus aureus Potentiates the Hemolytic Activity of Burkholderia cepacia Complex (Bcc) Bacteria. Current Microbiology, 2021, 78, 1864-1870.	2.2	3
9	Structural and Biochemical Characterization of the Novel CTX-M-151 Extended-Spectrum Î²-Lactamase and Its Inhibition by Avibactam. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	5
10	Assessing the Potency of Î²-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from Burkholderia multivorans. ACS Infectious Diseases, 2021, 7, 826-837.	3.8	6
11	Human Pleural Fluid and Human Serum Albumin Modulate the Behavior of a Hypervirulent and Multidrug-Resistant (MDR) Acinetobacter baumannii Representative Strain. Pathogens, 2021, 10, 471.	2.8	17
12	Interaction of Acinetobacter baumannii with Human Serum Albumin: Does the Host Determine the Outcome?. Antibiotics, 2021, 10, 833.	3.7	5
13	Activity of Imipenem-Relebactam against Multidrug- and Extensively Drug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli. Antimicrobial Agents and Chemotherapy, 2021, 65, e0133221.	3.2	11
14	A Î³-lactam siderophore antibiotic effective against multidrug-resistant Pseudomonas aeruginosa, Klebsiella pneumoniae, and Acinetobacter spp.. European Journal of Medicinal Chemistry, 2021, 220, 113436.	5.5	14
15	Effect of Serum Albumin, a Component of Human Pleural Fluid, on Transcriptional and Phenotypic Changes on Acinetobacter baumannii A118. Current Microbiology, 2021, 78, 3829-3834.	2.2	2
16	Interplay between Meropenem and Human Serum Albumin on Expression of Carbapenem Resistance Genes and Natural Competence in Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy, 2021, 65, e0101921.	3.2	10
17	A Standard Numbering Scheme for Class C Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	50
18	Resistance to Novel Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations. Infectious Disease Clinics of North America, 2020, 34, 773-819.	5.1	76

#	Article	IF	Citations
19	Structural Insights into Ceftobiprole Inhibition of Pseudomonas aeruginosa Penicillin-Binding Protein 3. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	9
20	A Î³-Lactam Siderophore Antibiotic Effective against Multidrug-Resistant Gram-Negative Bacilli. Journal of Medicinal Chemistry, 2020, 63, 5990-6002.	6.4	20
21	Structures of FOX-4 Cephamycinase in Complex with Transition-State Analog Inhibitors. Biomolecules, 2020, 10, 671.	4.0	4
22	Structural Insights into the Inhibition of the Extended-Spectrum Î²-Lactamase PER-2 by Avibactam. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	11
23	Population Structure, Molecular Epidemiology, and Î²-Lactamase Diversity among Stenotrophomonas maltophilia Isolates in the United States. MBio, 2019, 10, .	4.1	52
24	The latest advances in Î²-lactam/Î²-lactamase inhibitor combinations for the treatment of Gram-negative bacterial infections. Expert Opinion on Pharmacotherapy, 2019, 20, 2169-2184.	1.8	89
25	Structural Analysis of The OXA-48 Carbapenemase Bound to A â€œPoorâ€•Carbapenem Substrate, Doripenem. Antibiotics, 2019, 8, 145.	3.7	9
26	Resurrecting Old Î²-Lactams: Potent Inhibitory Activity of Temocillin against Multidrug-ResistantBurkholderiaSpecies Isolates from the United States. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	10
27	â€œSwitching Partnersâ€• Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Burkholderia cepacia Complex and Burkholderia gladioli Cystic Fibrosis Isolates. Journal of Clinical Microbiology, 2019, 57, .	3.9	24
28	Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	26
29	Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. Journal of Infectious Diseases, 2019, 220, 666-676.	4.0	51
30	Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone Î²-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent. MBio, 2019, 10, .	4.1	64
31	Beyond Piperacillin-Tazobactam: Cefepime and AAI101 as a Potent Î²-Lactamâ^'Î²-Lactamase Inhibitor Combination. Antimicrobial Agents and Chemotherapy, 2019, 63, .	3.2	65
32	Whole Genome Sequence Analysis of Burkholderia contaminans FFH2055 Strain Reveals the Presence of Putative Î²-Lactamases. Current Microbiology, 2019, 76, 485-494.	2.2	2
33	687. In vitro Activity of a New Generation Oxopyrazole Antibiotic Against Acinetobacter spp.. Open Forum Infectious Diseases, 2019, 6, S312-S312.	0.9	0
34	Human pleural fluid triggers global changes in the transcriptional landscape of Acinetobacter baumannii as an adaptive response to stress. Scientific Reports, 2019, 9, 17251.	3.3	27
35	Relebactam Is a Potent Inhibitor of the KPC-2 Î²-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	74
36	Strategic Approaches to Overcome Resistance against Gram-Negative Pathogens Using Î²-Lactamase Inhibitors and Î²-Lactam Enhancers: Activity of Three Novel Diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. Journal of Medicinal Chemistry, 2018, 61, 4067-4086.	6.4	117

#	Article	IF	Citations
37	Inactivation of the Pseudomonas-Derived Cephalosporinase-3 (PDC-3) by Relebactam. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	28
38	698. Nacubactam Inhibits Class A Î²-lactamases. Open Forum Infectious Diseases, 2018, 5, S251-S252.	0.9	0
39	2385. Ceftazidimeâ€“Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. Open Forum Infectious Diseases, 2018, 5, S711-S711.	0.9	1
40	Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa. MBio, 2018, 9, .	4.1	61
41	Sequence heterogeneity of the PenA carbapenemase in clinical isolates of Burkholderia multivorans. Diagnostic Microbiology and Infectious Disease, 2018, 92, 253-258.	1.8	10
42	Characterization of the AmpC Î²-Lactamase from Burkholderia multivorans. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	16
43	Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime forBurkholderia cepaciaComplex Isolates from Cystic Fibrosis Patients. ACS Infectious Diseases, 2017, 3, 502-511.	3.8	62
44	Exploring the Landscape of Diazabicyclooctane (DBO) Inhibition: Avibactam Inactivation of PER-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	14
45	WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent â€œÎ²-Lactam Enhancerâ€• Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-Î²-Lactamase-Producing High-Risk Clones. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	92
46	Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from Î²-Lactamase Protein Engineering. MBio, 2017, 8, .	4.1	93
47	Potent Î²-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	57
48	Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	52
49	Exploring the Role of the Î©-Loop in the Evolution of Ceftazidime Resistance in the PenA Î²-Lactamase from Burkholderia multivorans, an Important Cystic Fibrosis Pathogen. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	10
50	New Î²-Lactamase Inhibitors in the Clinic. Infectious Disease Clinics of North America, 2016, 30, 441-464.	5.1	138
51	Treatment options for infections caused by carbapenem-resistantEnterobacteriaceae: can we apply â€œprecision medicineâ€• to antimicrobial chemotherapy?. Expert Opinion on Pharmacotherapy, 2016, 17, 761-781.	1.8	135
52	Boronic Acid Transition State Inhibitors Active against KPC and Other Class A Î²-Lactamases: Structure-Activity Relationships as a Guide to Inhibitor Design. Antimicrobial Agents and Chemotherapy, 2016, 60, 1751-1759.	3.2	49
53	Exposing a Î²-Lactamase â€œTwistâ€• the Mechanistic Basis for the High Level of Ceftazidime Resistance in the C69F Variant of the Burkholderia pseudomallei PenI Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2016, 60, 777-788.	3.2	24
54	Inhibition of Klebsiella Î²-Lactamases (SHV-1 and KPC-2) by Avibactam: A Structural Study. PLoS ONE, 2015, 10, e0136813.	2.5	67

#	Article	IF	Citations
55	Avibactam and Inhibitor-Resistant SHV Î²-Lactamases. Antimicrobial Agents and Chemotherapy, 2015, 59, 3700-3709.	3.2	66
56	Variants of Î²-Lactamase KPC-2 That Are Resistant to Inhibition by Avibactam. Antimicrobial Agents and Chemotherapy, 2015, 59, 3710-3717.	3.2	85
57	Activities of ceftazidime, ceftaroline, and aztreonam alone and combined with avibactam against isogenic Escherichia coli strains expressing selected single Î²-lactamases. Diagnostic Microbiology and Infectious Disease, 2015, 82, 65-69.	1.8	38
58	Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV Î²-lactamases with single amino acid substitutions in the Î©-loop. Journal of Antimicrobial Chemotherapy, 2015, 70, 2279-2286.	3.0	105
59	Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2015, 59, 1020-1029.	3.2	121
60	New Î²-Lactamase Inhibitors: a Therapeutic Renaissance in an MDR World. Antimicrobial Agents and Chemotherapy, 2014, 58, 1835-1846.	3.2	258
61	A kinetic analysis of the inhibition of FOX-4 Â-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic Â-lactams and carbapenems. Journal of Antimicrobial Chemotherapy, 2014, 69, 682-690.	3.0	24
62	Reclaiming the Efficacy of Î²-Lactamâ€“Î²-Lactamase Inhibitor Combinations: Avibactam Restores the Susceptibility of CMY-2-Producing Escherichia coli to Ceftazidime. Antimicrobial Agents and Chemotherapy, 2014, 58, 4290-4297.	3.2	35
63	Non-phenotypic tests to detect and characterize antibiotic resistance mechanisms in Enterobacteriaceae. Diagnostic Microbiology and Infectious Disease, 2013, 77, 179-194.	1.8	74
64	Design and Exploration of Novel Boronic Acid Inhibitors Reveals Important Interactions with a Clavulanic Acid-Resistant Sulfhydryl-Variable (SHV) Î²-Lactamase. Journal of Medicinal Chemistry, 2013, 56, 1084-1097.	6.4	40
65	Insights into Î²-Lactamases from Burkholderia Species, Two Phylogenetically Related yet Distinct Resistance Determinants. Journal of Biological Chemistry, 2013, 288, 19090-19102.	3.4	47
66	Reply to FrÃ¨re: Covalent Trapping and Bacterial Resistance to Ceftazidime. Journal of Biological Chemistry, 2013, 288, 26968.	3.4	1
67	Novel Î²-lactamase inhibitors: a therapeutic hope against the scourge of multidrug resistance. Frontiers in Microbiology, 2013, 4, 392.	3.5	59
68	Understanding the Molecular Determinants of Substrate and Inhibitor Specificities in the Carbapenemase KPC-2: Exploring the Roles of Arg220 and Glu276. Antimicrobial Agents and Chemotherapy, 2012, 56, 4428-4438.	3.2	51
69	Exploring the Role of a Conserved Class A Residue in the Î©-Loop of KPC-2 Î²-Lactamase. Journal of Biological Chemistry, 2012, 287, 31783-31793.	3.4	84
70	Crystal Structures of KPC-2 Î²-Lactamase in Complex with 3-Nitrophenyl Boronic Acid and the Penam Sulfone PSR-3-226. Antimicrobial Agents and Chemotherapy, 2012, 56, 2713-2718.	3.2	46
71	Early Insights into the Interactions of Different Î²-Lactam Antibiotics and Î²-Lactamase Inhibitors against Soluble Forms of Acinetobacter baumannii PBP1a and Acinetobacter sp. PBP3. Antimicrobial Agents and Chemotherapy, 2012, 56, 5687-5692.	3.2	33
72	Inactivation of a class A and a class C Î²-lactamase by 6Î²-(hydroxymethyl)penicillanic acid sulfone. Biochemical Pharmacology, 2012, 83, 462-471.	4.4	16

#	Article	IF	Citations
73	Carbapenems: Past, Present, and Future. Antimicrobial Agents and Chemotherapy, 2011, 55, 4943-4960.	3.2	1,053
74	Molecular Investigations of PenA-mediated Î²-lactam Resistance in Burkholderia pseudomallei. Frontiers in Microbiology, 2011, 2, 139.	3.5	76
75	Exploring the Inhibition of CTX-M-9 by Î²-Lactamase Inhibitors and Carbapenems. Antimicrobial Agents and Chemotherapy, 2011, 55, 3465-3475.	3.2	31
76	Elucidating the role of Trp105 in the KPCâ€2 Î²â€lactamase. Protein Science, 2010, 19, 1714-1727.	7.6	57
77	Inhibitor Resistance in the KPC-2 Î²-Lactamase, a Preeminent Property of This Class A Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2010, 54, 890-897.	3.2	161
78	Substrate Selectivity and a Novel Role in Inhibitor Discrimination by Residue 237 in the KPC-2 Î²-Lactamase. Antimicrobial Agents and Chemotherapy, 2010, 54, 2867-2877.	3.2	53
79	Regulation of CorA Mg ²⁺ Channel Function Affects the Virulence of Salmonella enterica Serovar Typhimurium. Journal of Bacteriology, 2008, 190, 6509-6516.	2.2	36
80	The CorA Mg²⁺Channel Is Required for the Virulence ofSalmonella entericaSerovar Typhimurium. Journal of Bacteriology, 2008, 190, 6517-6523.	2.2	40
81	Bacterial homologs of eukaryotic membrane proteins: the 2-TM-GxN family of Mg2+transporters (Review). Molecular Membrane Biology, 2007, 24, 351-356.	2.0	22
82	Manganese Transport and the Role of Manganese in Virulence. Annual Review of Microbiology, 2006, 60, 187-209.	7.3	270
83	Penicillanic Acid Sulfones Inactivate the Extended-Spectrum Î²-Lactamase CTX-M-15 through Formation of a Serine-Lysine Cross-Link: an Alternative Mechanism of Î²-Lactamase Inhibition. MBio, 0, , .	4.1	2